I think the FDA has now given a route-map to approval, and so subsequent entrants will have an easier time of it than MNTA did. The Amphastar disclosures added to my conviction on this.
It sounds like you don't regard MNTA's IP as an impediment. Also, which Amphastar disclosures are you referring to?